Simple laboratory tools for predicting survival in cancer patients with brain metastases


  • Pre-radiosurgery neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and the modified Glasgow Prognostic Score (mGPS) were able to predict survival in patients with non-small-cell lung cancer (NSCLC) prior to radiosurgery for brain metastases (BM).

Why this matters

  • The above mentioned laboratory parameters have been used to predict survival of patients with NSCLC. Prognostic tools also exist for predicting the survival of patients with BM, but none have evaluated prognostic tools for patients with both complications.

  • The results of this study may help facilitate clinical decision making in patients with NSCLC who plan to undergo radiosurgery for BM.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.